Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/09/23
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality PortfolioGlobeNewsWire • 10/16/23
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 09/19/23
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 InhibitorsGlobeNewsWire • 09/11/23
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as ChairmanGlobeNewsWire • 08/24/23
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 08/10/23
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 05/15/23
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' NowZacks Investment Research • 04/24/23
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to BuyZacks Investment Research • 04/04/23
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 03/30/23
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual MeetingGlobeNewsWire • 03/16/23
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 03/01/23
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common StockGlobeNewsWire • 02/27/23
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common StockGlobeNewsWire • 02/23/23
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors SummitGlobeNewsWire • 01/19/23
Karolinska Development's portfolio company Aprea Therapeutics doses the first patient in a clinical phase 1/2a study of ATRN-119GlobeNewsWire • 01/12/23
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 11/09/22